SEC Form 4 · accession 0001209191-15-023360
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jamie Christensen
Officer — SVP & Chief Scientific Officer
Period of report
Mar 5, 2015
Accepted (ET)
Mar 6, 2015 · 1:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 5, 2015 | M | 6,000 | $8.50 | A | 7,250 | D | |
| Common StockF2 | Mar 5, 2015 | S | 4,000 | $25.05 | D | 3,250 | D | |
| Common StockF3 | Mar 5, 2015 | S | 2,000 | $26.14 | D | 1,250 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F4 | $8.50 | Mar 5, 2015 | M | 6,000 | D | — | Jul 16, 2020 | Common Stock | 6,000 | 18,000 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.02 to $25.1039, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.193, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F4Twenty percent (20%) of the shares subject to the stock option vested and became exercisable on the grant date of the option (July 17, 2013), and an additional 20% shall vest and become exercisable each year on the anniversary of the grant date.